NASDAQ:TNYA
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. reported net income of −$90.6M in fiscal 2025. Free cash flow was −$68.9M, and the diluted share count rose 80.3%.Summary generated from Tenaya Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−83.8%
Debt / equityn/a
Free cash flow−$68.9M
FCF marginn/a
Share count change+80.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −73 | −126 | −131 | −116 | −93 |
| Net income | −73 | −124 | −124 | −111 | −91 |
| Free cash flow | −86 | −125 | −103 | −92 | −69 |
Recent filings
- 4Insider transaction report
Sep 11, 2026 - 4Insider transaction report
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KTermination of a material agreement
Jul 2, 2026 - 8-KDirector or officer change
Jun 29, 2026 - 8-KDirector or officer change
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026